PsiOvi Staging Model for Schizophrenia (PsiOvi SMS): A New Internet Tool for Staging Patients with Schizophrenia
- PMID: 38599765
- PMCID: PMC11059252
- DOI: 10.1192/j.eurpsy.2024.17
PsiOvi Staging Model for Schizophrenia (PsiOvi SMS): A New Internet Tool for Staging Patients with Schizophrenia
Abstract
Background: One of the challenges of psychiatry is the staging of patients, especially those with severe mental disorders. Therefore, we aim to develop an empirical staging model for schizophrenia.
Methods: Data were obtained from 212 stable outpatients with schizophrenia: demographic, clinical, psychometric (PANSS, CAINS, CDSS, OSQ, CGI-S, PSP, MATRICS), inflammatory peripheral blood markers (C-reactive protein, interleukins-1RA and 6, and platelet/lymphocyte [PLR], neutrophil/lymphocyte [NLR], and monocyte/lymphocyte [MLR] ratios). We used machine learning techniques to develop the model (genetic algorithms, support vector machines) and applied a fitness function to measure the model's accuracy (% agreement between patient classification of our model and the CGI-S).
Results: Our model includes 12 variables from 5 dimensions: 1) psychopathology: positive, negative, depressive, general psychopathology symptoms; 2) clinical features: number of hospitalizations; 3) cognition: processing speed, visual learning, social cognition; 4) biomarkers: PLR, NLR, MLR; and 5) functioning: PSP total score. Accuracy was 62% (SD = 5.3), and sensitivity values were appropriate for mild, moderate, and marked severity (from 0.62106 to 0.6728).
Discussion: We present a multidimensional, accessible, and easy-to-apply model that goes beyond simply categorizing patients according to CGI-S score. It provides clinicians with a multifaceted patient profile that facilitates the design of personalized intervention plans.
Keywords: clinical tool; empirical staging model; multidimensional model; personalized intervention; schizophrenia.
Conflict of interest statement
The authors declare no conflict of interest related to the submitted work.
Figures



Similar articles
-
Validation of the German version of the Clinical Assessment Interview for Negative Symptoms (CAINS).Psychiatry Res. 2014 Dec 15;220(1-2):659-63. doi: 10.1016/j.psychres.2014.07.070. Epub 2014 Aug 1. Psychiatry Res. 2014. PMID: 25138895
-
The Associations of Neutrophil-Lymphocyte, Platelet-Lymphocyte, Monocyte-Lymphocyte Ratios and Immune-Inflammation Index with Negative Symptoms in Patients with Schizophrenia.Biomolecules. 2023 Feb 4;13(2):297. doi: 10.3390/biom13020297. Biomolecules. 2023. PMID: 36830666 Free PMC article.
-
Assessing negative symptoms in schizophrenia: Validity of the clinical assessment interview for negative symptoms in Singapore.Schizophr Res. 2019 Apr;206:177-182. doi: 10.1016/j.schres.2018.11.029. Epub 2018 Dec 14. Schizophr Res. 2019. PMID: 30558979
-
Relationships between global assessment of functioning and other rating scales in clinical trials for schizophrenia.Psychiatry Res. 2015 Jun 30;227(2-3):265-9. doi: 10.1016/j.psychres.2015.02.024. Epub 2015 Apr 1. Psychiatry Res. 2015. PMID: 25882098 Review.
-
The Gold Standard Diagnosis of Schizophrenia is Counterproductive: Towards Quantitative Research and Diagnostic Algorithmic Rules (RADAR) and their Derived Qualitative Distinct Classes.Curr Top Med Chem. 2024;24(20):1799-1815. doi: 10.2174/0115680266295129240415120646. Curr Top Med Chem. 2024. PMID: 38644707 Review.
Cited by
-
Anticholinergic load: A commonly neglected and preventable risk to cognition during schizophrenia treatment?Schizophr Res Cogn. 2024 May 12;37:100317. doi: 10.1016/j.scog.2024.100317. eCollection 2024 Sep. Schizophr Res Cogn. 2024. PMID: 38745931 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous